SenoRx Announces Third Quarter 2009 Conference Call and Webcast


IRVINE, Calif., Oct. 5, 2009 (GLOBE NEWSWIRE) -- SenoRx Inc. (Nasdaq:SENO) today announced it will host its investor conference call to review its third quarter 2009 financial results on Wednesday, November 4 at 8:00 a.m. PST (11:00 a.m. EST). The call will be open to all investors live via the Investor Relations section of the SenoRx web site at http://investor.senorx.com/events.cfm. A replay of the call will be available on the company's web site approximately 90 minutes after the call concludes. It will also be available to be downloaded as a podcast. SenoRx's financial results press release is expected to be released after market close on Tuesday, November 3.


 Details:
 What: SenoRx's Third Quarter 2009 Investor Conference Call and Webcast
 Date: Wednesday, November 4
 Time: 8:00 a.m. PST/11:00 a.m. EST
 How:  Via telephone:  Domestic:  877-627-6511;
                       International: 719-325-4922
       Via Internet:   http://investor.senorx.com/events.cfm

About SenoRx

SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical devices used by breast care specialists for the diagnosis and treatment of breast cancer, including its EnCor(R) vacuum-assisted breast biopsy system and Contura(TM) MLB catheter for delivering radiation to the tissue surrounding the lumpectomy cavity following surgery for breast cancer. SenoRx's field sales organization serves over 2,000 breast diagnostic and treatment centers in the United States and Canada. In addition, SenoRx sells several of its products through distribution partners in more than 30 countries outside the U.S. and Canada. The company's line of breast care products includes biopsy disposables, biopsy capital equipment, diagnostic adjunct products and therapeutic disposables. SenoRx is developing additional minimally invasive products for the diagnosis and treatment of breast cancer. For more information, visit the company's website at www.senorx.com.

The SenoRx, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3605


            

Kontaktdaten